All of these data indicate that the impaired expression of Nrf2 as a result of redox imbalance can be considered an important therapeutic target in the search for promising therapeutic agents for the treatment of both malignant neoplasms and Alzheimer’s disease. This evidence concerns the gene NFE2L2 and cancer.